The JCOG1019 trial compared active surveillance and intravesical bacillus Calmette-Guérin (BCG) in patients with high-grade T1 bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB. Active surveillance was noninferior to intravesical BCG in terms of survival free from cystectomy, muscle-invasive disease, metastasis, and death.
European Urology published a clinical update in Research Highlights on 21 Jan 2026.
The item focuses on Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
Review the original article for the full source wording and details.